Q1. How many patients were treated in December 2021 (or latest available month) by the dermatology department with the following drugs:
1. Abrocitinib (Cibinqo)
2. Baricitinib (Olumiant)
3. Bimekizumab (Bimzelx)
4. Brodalumab (Kyntheum)
5. Dupilumab (Dupixent)
6. Ixekizumab (Taltz)
7. Risankizumab (Skyrizi)
8. Guselkumab (Tremfya)
9. Secukinumab (Cosentyx)
10. Tildrakizumab (Ilumetri)
11. Tralokinumab (Adtralza)
12. Ustekinumab (Stelara)
Q2. How many patients were treated in December 2021 (or latest available month) by the rheumatology department with the following drugs:
1. Baricitinib (Olumiant)
2. Filgotinib (Jyseleca)
3. Guselkumab (Tremfya)
4. Ixekizumab (Taltz)
5. Risankizumab (Skyrizi)
6. Secukinumab (Cosentyx)
7. Tofacitinib (Xeljanz)
8. Upadacitinib (Rinvoq)
9. Ustekinumab (Stelara)

Treatment of dermatological and rheumatological conditions. 040222.docx